Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-641-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$96.30 million
Profitability
Miscellaneous
Employees327
OptionableOptionable
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) released its quarterly earnings results on Tuesday, May, 1st. The medical equipment provider reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The medical equipment provider earned $24.70 million during the quarter, compared to analysts' expectations of $23.66 million. Intersect ENT had a negative return on equity of 17.62% and a negative net margin of 20.00%. The firm's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) EPS. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
How can I listen to Intersect ENT's earnings call?
Intersect ENT will be holding an earnings conference call on Monday, February 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8448500548.
What guidance has Intersect ENT issued on next quarter's earnings?
Intersect ENT issued an update on its first quarter 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $28.36 million.Intersect ENT also updated its FY 2018 guidance to EPS.
What price target have analysts set for XENT?
7 Wall Street analysts have issued 1-year target prices for Intersect ENT's shares. Their predictions range from $28.00 to $48.00. On average, they expect Intersect ENT's stock price to reach $38.6667 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price. View Analyst Price Targets for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (1/22/2019)
- 2. Northland Securities analysts commented, "We had specifically referenced this drug and these Phase-III studies as risks on the horizon for SINUVA in our note dated 10/03/18. The Phase – III data raise many questions in our mind about SINUVA outlook and the competitive landscape. Caution is warranted vis-a-vis SINUVA. Key Points The f/u for the 2-trials was 24-wks, Dupilumab + mometasone furoate (Nasonex) spray 51% reduction in nasal congestion / obstruction severity vs. 15% for the control arm of mometasone furoate spray in SINUS-24 trial. The numbers stood at 57% and 19% for SINUS-52 trial." (10/17/2018)
- 3. BTIG Research analysts commented, "Following this morning’s early earnings announcement, management discussed the issues underlying the weak report and reduced sales guidance. Most troubling to us was that instead of SINUVA being easily available via the specialty pharmacy channel, many payors are requiring doctors to either use a payor-affiliated specialty pharmacy partner or to use a buy-and-bill approach. This means doctors must pay to acquire SINUVA, then bill for it and hope they are paid back. While XENT mgmt believes this hurdle can be overcome by showing reluctant docs proof of payment and expanding the salesforce, we think it will be more difficult to change the way ENTs operate. We cut our SINUVA sales estimate for 2H and beyond while also dampening modeled growth rates for PROPEL." (8/2/2018)
- 4. Canaccord Genuity analysts commented, "We remain buyers ahead of trial data coming up in 4Q18 We believe the stock’s pullback presents opportunity ahead of a catalyst-rich period that is coming up in the near to medium-term. Specifically, we await results on long- term safety of rimegepant (acute treatment of migraine) and a Phase 3 trial on the orally-dissolving tablet (ODT) formulation of rimegepant. Given the behavior of the molecule in two Phase 3 trials so far (see here) and a validated mechanism (Allergan also reported positive results for its ubrogepant; see here), we expect these results to support a potential filing of rimegepant in 2019. a more detailed list of BHVN-related catalysts. We also continue to believe that rimegepant could be a meaningful player in the market for the acute treatment of migraine, and we are reiterating our BUY on BHVN." (8/1/2018)
Has Intersect ENT been receiving favorable news coverage?
News coverage about XENT stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intersect ENT earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Nevro (NVRO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Cardiovascular Systems (CSII), Orthofix Medical (OFIX), K2M Group (KTWO) and Luminex (LMNX).
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
- Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
- Mr. Richard E. Kaufman, Technical Advisor (Age 57)
- Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.05%), Westfield Capital Management Co. LP (2.24%), Northern Trust Corp (1.32%), Geode Capital Management LLC (1.12%), Broadfin Capital LLC (0.94%) and Bellevue Group AG (0.78%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.
Which institutional investors are selling Intersect ENT stock?
XENT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Bank of America Corp DE, Barclays PLC, Kopp Investment Advisors LLC, Principal Financial Group Inc., Strs Ohio and GSA Capital Partners LLP. Company insiders that have sold Intersect ENT company stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.
Which institutional investors are buying Intersect ENT stock?
XENT stock was purchased by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, SG Americas Securities LLC, Amundi Pioneer Asset Management Inc., Pura Vida Investments LLC, Broadfin Capital LLC, Geode Capital Management LLC, D. E. Shaw & Co. Inc. and Rhumbline Advisers. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $34.34.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $1.05 billion and generates $96.30 million in revenue each year. The medical equipment provider earns $-16,360,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Intersect ENT employs 327 workers across the globe.
What is Intersect ENT's official website?
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
